Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients

Hematological Oncology

Volumn 35, Issue 4, 2017, Pages 828-834

  Cattaneo, Chiara ^a   Oberti, Margherita ^a   Skert, Cristina ^b   Passi, Angela ^a   Farina, Mirko ^a   Re, Alessandro ^a   Tozzi, Paola ^a   Borlenghi, Erika ^a   Rossi, Giuseppe ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

hemophagocytic lymphohistiocytosis; hemophagocytic syndrome; hemophagocytosis; immune activation; outcome of secondary hemophagocytic syndrome

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CLINICAL ARTICLE; CONCURRENT INFECTION; CONNECTIVE TISSUE DISEASE; CYTOMEGALOVIRUS INFECTION; EDEMA; EPSTEIN BARR VIRUS INFECTION; ERYTHROPHAGOCYTOSIS; FEMALE; FEVER; FOLLOW UP; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERFERRITINEMIA; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SPLENOMEGALY; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; T CELL LYMPHOMA; VIRUS INFECTION; COMPLICATION; MIDDLE AGED; MORTALITY; SURVIVAL RATE; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84973169237     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2314     Document Type: Article

References (24)

1. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev 2015; 26(3): 263–80.
2. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol 2013; 161(5): 609–622.
3. Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program 2013; 2013: 605–611.
4. Zhang L, Zhou J, Sokol L. Hereditary and acquired hemophagocytic lymphohistiocytosis. Cancer Control 2014; 21(4): 301–312.
5. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121(26): 5154–7.
6. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic-disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011; 50(2): 417–9.
7. Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol 2014; 141(1): 62–71.
8. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48(2): 124–131.
9. Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011; 118(17): 4577–4584.
10. Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 2015; 90(3): 220–224.
11. Li J, Wang Q, Zheng W, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore) 2014; 93(2): 100–105.
12. Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol 2015; 168(1): 63–68.
13. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 2014; 89(4): 484–492.
14. Schram AM, Comstock P, Campo M, et al. Hemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol 2016; 172(3): 412–9.
15. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014; 66(9): 2613–2620.
16. Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 2016; 75(3): 481–9.
17. Li F, Li P, Zhang R, et al. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol 2014; 31(4): 902.
18. Machaczka M, Vaktnäs J, Klimkowska M, Hägglund H. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma 2011; 52(4): 613–619.
19. Yu JT, Wang CY, Yang Y, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol 2013; 92(11): 1529–1536.
20. Shin HJ, Chung JS, Lee JJ, et al. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci 2008 Jun; 23(3): 439–444.
21. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012 Jun; 13(4): 289–98.
22. Wang Y, Huang W, Wei N, et al. Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Zhonghua Xue Ye Xue Za Zhi 2014; 35(10): 901–904.
23. Al Asad O, Salam A, Mannem S, Ninan M, Markowitz A, Jana B. Alternative therapy for epstein-barr virus related hemophagocytic lymphohistiocytosis. Case Rep Oncol Med 2015; 2015: 508387.
24. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013; 162(3): 376–382.